These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 6952964)

  • 41. A phase II study with teniposide (VM26) in patients with progressed or relapsed small cell lung cancer (SCLC).
    Tummarello D; Guidi F; Di Furia L; Gramazio A; Menichetti E; Cellerino R
    J Chemother; 1989 Feb; 1(1):64-7. PubMed ID: 2542470
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Phase II study of vindesine in hematological malignancies].
    Gan To Kagaku Ryoho; 1983 Dec; 10(12):2509-15. PubMed ID: 6580841
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Two epipodophyllotoxin derivatives, VM 26 and VP 16213, in the treatment of leukemias, hematosarcomas, and lymphomas.
    Mathé G; Schwarzenberg L; Pouillart P; Oldham R; Weiner R; Jasmin C; Rosenfeld C; Hayat M; Misset JL; Musset M; Schneider M; Amiel JL; De Vassal F
    Cancer; 1974 Oct; 34(4):985-92. PubMed ID: 4608026
    [No Abstract]   [Full Text] [Related]  

  • 44. Phase II trial of VM-26 in patients with metastatic malignant melanoma.
    Bellet RE; Catalno RB; Mastrangelo MJ; Berd D; Koons LS
    Cancer Treat Rep; 1978 Mar; 62(3):445-7. PubMed ID: 348313
    [No Abstract]   [Full Text] [Related]  

  • 45. [Treatment of acute refractory lymphoblastic leukemia in the adult with VM-26 and ARA-C].
    Rafecas FJ; Sanz MA
    Sangre (Barc); 1984; 29(6):1052-3. PubMed ID: 6598235
    [No Abstract]   [Full Text] [Related]  

  • 46. A phase II study of bisantrene in malignant lymphomas. A Southwest Oncology Group Study.
    Miller TP; Cowan JD; Neilan BA; Jones SE
    Cancer Chemother Pharmacol; 1986; 16(1):67-9. PubMed ID: 3940222
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Phase II trial of teniposide in previously treated and untreated patients with advanced colorectal carcinoma: an Illinois Cancer Council Trial.
    Locker GY; Lanzotti V; Khandekar JD; Sweet D; Shaw J; Bitran J; Gordon L; Krauss S; Johnson C
    Cancer Treat Rep; 1986 Feb; 70(2):307-8. PubMed ID: 3948195
    [No Abstract]   [Full Text] [Related]  

  • 48. Evaluation of VP-16-213 in malignant lymphoma and melanoma.
    Cecil JW; Quagliana JM; Coltman CA; Al-Sarraf M; Thigpen T; Groppe CW
    Cancer Treat Rep; 1978 May; 62(5):801-3. PubMed ID: 657164
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Teniposide in the treatment of non-small cell lung carcinoma.
    Giaccone G; Donadio M; Ferrati P; Bonardi G; Ciuffreda L; Bagatella M; Calciati A
    Cancer Treat Rep; 1987 Jan; 71(1):83-5. PubMed ID: 3024829
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Combination chemotherapy with VM-26, adriamycin bleomycin, and prednisone as a secondary treatment of malignant lymphoma.
    Goldhirsch A; Pirovino M; Sonntag RW; Tschopp L; Ryssel HJ; Brunner KW
    Cancer Treat Rep; 1980; 64(2-3):335-7. PubMed ID: 6157468
    [TBL] [Abstract][Full Text] [Related]  

  • 51. VM-26 and cytarabine combination chemotherapy in refractory or relapsed adult acute lymphoblastic leukemia.
    Carella AM; Santini G; Martinengo M; Giordano D; Nati S; Congiu A; Risso M; Vimercati R; Cerri R; Rossi E
    Haematologica; 1984; 69(6):747-51. PubMed ID: 6441752
    [No Abstract]   [Full Text] [Related]  

  • 52. Blood and neoplastic diseases. Rational approach to the chemotherapy of human malignant disease-II.
    Crowther D
    Br Med J; 1974 Oct; 4(5938):216-8. PubMed ID: 4529039
    [No Abstract]   [Full Text] [Related]  

  • 53. Comparative trial of two teniposide-based combination chemotherapy regimens for the treatment of advanced malignant lymphomas.
    O'Connell MJ; Anderson J; Merrill JM; Bennett JM; Glick JH; Berard CW; Neiman RS; Brodovsky HS
    Cancer Treat Rep; 1982 Dec; 66(12):2021-5. PubMed ID: 6814757
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phase II study of VM-26 in adult malignancies.
    Spremulli E; Schulz JJ; Speckhart VJ; Wampler GL
    Cancer Treat Rep; 1980 Jan; 64(1):147-9. PubMed ID: 7379049
    [No Abstract]   [Full Text] [Related]  

  • 55. [Contribution of anthracyclines in treatment of lymphoproliferative disorders].
    Coiffier B
    Pathol Biol (Paris); 1987 Jan; 35(1):75-8. PubMed ID: 2436132
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Teniposide (VM-26) and ara-C in the treatment of adult acute lymphoblastic leukemia.
    Linker CA; Levitt LJ; O'Donnell M; Ries CA; Forman SJ
    Semin Oncol; 1987 Jun; 14(2 Suppl 1):78-85. PubMed ID: 3473686
    [No Abstract]   [Full Text] [Related]  

  • 57. Acute leukemia occurring in a primary neoplasia (secondary leukemia). A Review of biological, epidemiological and clinical aspects.
    Brusamolino E; Pagnucco G; Bernasconi C
    Haematologica; 1986; 71(1):60-83. PubMed ID: 3084360
    [No Abstract]   [Full Text] [Related]  

  • 58. Pharmacokinetics and efficacy of i.v. and i.p. VM26 chemotherapy in mice bearing Krebs II ascitic tumors.
    Canal P; Bugat R; Rokoszak B; Berg D; Soula G; Roche H
    Eur J Cancer Clin Oncol; 1986 Jul; 22(7):765-71. PubMed ID: 3770034
    [TBL] [Abstract][Full Text] [Related]  

  • 59. m-AMSA: phase II trial in advanced lymphoma and leukemia.
    Case DC
    Am J Clin Oncol; 1984 Aug; 7(4):357-60. PubMed ID: 6588746
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The treatment of chronic lymphocytic leukaemia and malignant lymphomas with dipine.
    Cattaneo N; De Cataldo F; Pensabene A; Tiso R
    Oncology; 1967; 21(1):61-71. PubMed ID: 4870984
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.